Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of aesthetics and medical dermatology. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Bids due on December 2, 2019 by 5:00 p.m. Eastern Time Bids due on December 2, 2019 by 5:00 p.m. Eastern Time

Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures

-- Sienna’s common stock to remain conditionally listed during the Chapter 11 asset sale process

Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice

WESTLAKE VILLAGE, Calif., Oct.  07, 2019  (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has filed a Premarket Notification 510(k) submission to  the U.S. Food and Drug Administration (FDA) for SNA-001, a topical pre-treatment to standard laser devices to remove unwanted light hair, and has received acknowledgement from FDA that the submission has been accepted. 

Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair

WESTLAKE VILLAGE, Calif., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has elected to file a voluntary petition to allow restructuring under Chapter 11 of the Bankruptcy Code.

News for Sienna Biopharmaceuticals Stock (SNNA)